ClinicalTrials.gg
CompletedNCT02604823Updated Nov 2, 2016

A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)

A Phase 4 interventional study of Peginterferon alfa-2a in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
307
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
8th of 59
307 · median 114
Started
2003
the only one that year
Phase 4
29 of 59
none open now
Registered
44th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 8th largest by enrollment, is the only one that started in 2003, is one of 29 in phase 4, and was the 44th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive, interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV. Following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants between 18 to 65 years of age
  • HBeAg-positive chronic
  • Treatment-naive, or have received and have not responded to or have on either conventional interferon or lamivudine therapy.

Exclusion criteria

Exclusion Criteria:

  • Antiviral or interferon-based therapy for chronic within 6 months of enrollment
  • Co-infection with active hepatitis A, C or D virus or with (HIV)
  • Evidence of decompensated liver disease
  • Medical condition associated with chronic liver disease other than viral hepatitis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Group A (Naïve Participants)

    Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms \[mcg\]) subcutaneously once weekly for 48 weeks.

    Drug: Peginterferon alfa-2a

  • Experimental
    Group B (Conventional Interferon Pretreated Participants)

    Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.

    Drug: Peginterferon alfa-2a

  • Experimental
    Group C (Lamivudine Pretreated Participants)

    Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.

    Drug: Peginterferon alfa-2a

Interventions

  • Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Percentage of participants with HBV deoxyribonucleic acid (DNA) less than (<) 100,000 copies per milliliters (copies/mL)

    Time frame: 72 weeks

  2. Percentage of participants with HBeAg seroconversion

    Time frame: 72 weeks

Secondary outcomes

  1. Number of participants who achieved HBV DNA levels below limit of detection

    Time frame: Weeks 48 and 72

  2. Number of participants with HBsAg loss

    Time frame: Weeks 48 and 72

  3. Number of participants with both Hepatitis B Surface Antigen (HBsAg) loss and presence of Anti-HBs

    Time frame: Weeks 48 and 72

  4. Number of participants with alanine aminotransferase (ALT) normalization

    Time frame: Weeks 48 and 72

  5. Number of participants with combined response (HBV DNA <100,000 copies/mL, HBeAg loss, and ALT normalization)

    Time frame: Weeks 48 and 72

  6. Incidence of adverse events

    Time frame: up to 72 weeks

07

Study locations

3 sites
  • Beijing, 100011, China
  • Guangzhou, 510630, China
  • Shanghai, 200025, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
Nov 13, 2015
Start
Nov 2003
Primary completionActual
Nov 2005
CompletionActual
Nov 2005
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02604823
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 13, 2015
Start date
Nov 2003
Primary completion
Nov 2005
Completion
Nov 2005
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion